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Cardiovascular inflammation is a biological process characterized by the immune cell 
response to harmful stimuli within the cardiovascular system, wherein homeostasis is 
reestablished by neutralizing the insult and promoting the repair of the damaged tissue.  
However, a failure in the resolution of inflammation can lead to a maladaptive inflammatory 
response, contributing to the development of cardiovascular diseases such as aortic valve 
stenosis (AVS) and atherosclerosis, as well as vascular complications such as intimal 
hyperplasia.  
Omega-3 polyunsaturated fatty acids (n-3 PUFA) serve as a substrate for the generation of a 
group of bioactive specialized pro-resolving lipid mediators (SPMs) that mediate the 
resolution of inflammation. The SPM resolvin E1 (RvE1) derived from eicosapentaenoic acid 
reduces cardiovascular inflammation by signaling through the G protein-coupled receptor 
ChemR23.  
The aims of the current thesis were to establish the role of ChemR23 and its activation via 
RvE1 in the context of AVS, intimal hyperplasia, and atherosclerotic plaque calcification.  
In Article I, we reported for the first time that n-3 PUFA as well as RvE1 were decreased in 
calcified regions compared with non-calcified parts of human aortic valves from AVS 
patients. Stimulation of valve interstitial cells with RvE1 reduced cell calcification after 
phosphate supplementation. Genetic deletion of ChemR23 in apolipoprotein E-deficient 
(Apoe-/-) mice exacerbated hemodynamic and histological signs of AVS. Moreover, presence 
of the Fat-1 transgene (Fat-1tg), which enables the endogenous synthesis of n-3 PUFA, halted 
AVS progression by reducing hemodynamic and histological signs of AVS, and promoting 
M2 macrophage polarization in the mouse aortic valves. Importantly, Fat-1tg effects were 
only detected in the presence of ChemR23, suggesting that the beneficial actions were 
mediated via RvE1 signaling through ChemR23.  
In Article II, we showed that ChemR23 genetic deletion in mice increased the development 
of intimal hyperplasia after a carotid ligation. In vitro, ChemR23-deficient vascular smooth 
muscle cells (VSMCs) exhibited lower proliferation compared with ChemR23 wild-type 
VSMC. Moreover, ChemR23-deficient macrophages presented a more pro-inflammatory 
phenotype. Finally, conditioned media transfer from ChemR23-deficient macrophages to 
VSMCs increased VSMC proliferation compared with conditioned media from ChemR23 
wild-type macrophages. This points to a dual effect of ChemR23 in the vasculature depending 
on the degree of inflammation, with ChemR23 directly stimulating VSMC proliferation and 
at the same time suppressing macrophage-induced VSMC proliferation. 
In Article III, we demonstrated that the presence of Fat-1tg increased n-3 PUFA 
incorporation in atherosclerotic plaques of Apoe-/- mice, and decreased atherosclerotic plaque 
calcification. As also seen in aortic valves, ChemR23 deletion increased murine 
atherosclerotic plaque calcification independently of the local levels of n-3 PUFA, 
demonstrating the importance of a correct signaling through ChemR23. Moreover, in 
atherosclerotic plaques of Fat-1tgxApoe-/- mice, the protein expression of the M2-macrophage 
marker arginase-1 was increased and ChemR23 deletion enhanced the levels of tissue non-
specific alkaline phosphatase (TNAP). 
In conclusion, the results included in this thesis demonstrate the importance of ChemR23 
signaling in cardiovascular inflammation and provide novel mechanistic insights into the 
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Cardiovascular inflammation is characterized by the biological response of the immune 
system to harmful stimuli within the cardiovascular system. This process may happen at any 
level of the cardiovascular tree, for example at the aortic valve or vasculature.  
Inflammation is therefore a biological defense mechanism in order to reestablish 
homeostasis. However, a maladaptive inflammatory response may become chronic, thus 
contributing to the development of inflammatory cardiovascular diseases such as aortic valve 
stenosis (AVS) and atherosclerosis. 
1.1 THE AORTIC VALVE 
The aortic valve is an avascular tissue composed by three semilunar leaflets or cusps. The 
aortic valve leaflets are attached to the aortic wall and open and close with every heartbeat, 
maintaining the unidirectional blood flow from the left ventricle to the aorta when open 
during systole, and allowing the optimal refill of the ventricle while preventing regurgitation 
of blood from the aorta when closed during diastole1. 
The non-coapted region of the valve leaflet is called the belly2. Behind the belly of the 
leaflets, the aortic root gives rise to the sinuses of Valsalva3, where the coronary arteries 
begin. During diastole, when the valve is closed, the blood in the aorta exerts a backpressure 
of 80 mm Hg on the belly of the leaflets, keeping them stretched and completely closed. In 
systole, the pressure on the leaflets is reduced and they transition into a relaxed state, moving 
towards the aortic wall4 (Figure 1). The correct mobility and pliability of the valve, 
determined by the cellular and molecular micro-architecture, dictates its optimal 
functionality5. 
Figure 1. Schematic two dimensional representation of the aortic valve in diastole . 
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1.1.1 Micro-architecture of the aortic valve  
The micro-architecture of the aortic valve leaflets is the intrinsic determinant of a correct valve 
function and durability6. Each leaflet is composed of an external coat layer of valvular 
endothelial cells (VECs) which covers the surface of both the ventricular and aortic side. On 
the aortic side, below the endothelium, is the fibrosa layer. The fibrosa is mainly composed of 
tightly packed collagen fibers and valvular interstitial cells (VICs). Below the fibrosa, a well-
organized layer of glycosaminoglycans (GAGs) and VICs exists called the spongiosa. Between 
the spongiosa and the endothelial layer of the ventricular side is a layer of elastin and VICs 
called the ventricularis7 (Figure 2).  
Collagen, GAGs and elastin are extracellular matrix (ECM) components with specific and 
well-defined roles in valve function8. Collagen, in particular collagen type I, is important for 
valve durability9. Elastin provides tissue elasticity while GAGs facilitate rearrangements of the 
other two ECM components in every cardiac cycle, providing cushioning and a shear absorbing 
function10.  
 




VICs constitute the main cell population in the aortic valve. This cell type has a mesenchymal 
origin and possesses the capacity to modify the ECM in order to maintain an optimal aortic 
valve functionality11.  
At least 5 different types of VICs have been identified within the aortic valve, and are 
characterized by the presence of different markers: embryonic progenitor 
endothelial/mesenchymal cells, progenitor VICs (pVICs), quiescent VICs (qVICs), activated 
VICs (aVICs) and osteoblastic VICs (oVICs)12.  
The embryonic progenitor endothelial/mesenchymal cells have been identified during valve 
formation during heart development. This process is initiated by the endocardial cushion 
formation, which is accompanied by an endothelial to mesenchymal transition (EndMT) of 
endocardial cells during embryogenesis, giving rise to the aortic valve13, 14. 
qVICs are the main population of VICs present in healthy mature human aortic valves. They 
actively differentiate into the other VIC types under abnormal conditions such as injury or 
disease15. 
pVICs, or valvular stem cells, are not very well characterized yet, but they may play an 
important role in aortic valve repair12, 16.  
aVICs express alpha smooth muscle actin (α-SMA), which shows their activation and 
differentiation into myofibroblast-like cells. aVICs possess the ability to modify ECM 
components by altering proteolytic pathways through the expression of matrix 
metalloproteinases (MMPs) and cathepsins, increasing proliferation, and stimulating fibrotic 
pathways by the expression of cytokines such as transforming growth factor beta (TGFβ)17. 
oVICs are a subset of VICs that actively regulate the calcification process in AVS, a key event 
in the development of the disease12, by upregulating the expression of bone morphogenetic 
protein 2 (BMP2), and runt-related transcription factor 2 (Runx2). This induces the activation 
of calcification-related signaling pathways such as the Wnt/Lrp5/β-catenin pathway, which in 
turn increases local calcification18. 
It is important to mention that the classification of VICs into different groups has been primarily 
defined by the presence immunohistochemical markers. Future studies, using for example 
single cell sequencing, may provide further insights. For instance, a recent study using single 
cell-RNA sequencing has shown differential transcriptomic patterns between VICs from 
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atrioventricular valves and semilunar valves. The same study demonstrates that VICs increase 
apoptosis during the remodeling phase in the developmental period of the heart14. 
1.1.3 VECs 
VECs cover the complete structure of the aortic valve leaflets and promote valve integrity. 
Despite the similarities between VECs and arterial endothelial cells, they differ in several 
aspects. For instance, VECs align to blood flow in a perpendicular manner in the response to 
shear stress, whereas arterial endothelial cells remain parallel19.  
Moreover, the anatomical location of VECs within the aortic valve determines differential 
transcriptomic profiles. For example, VECs from the ventricular side of the aortic valve contain 
a higher expression of the atheroprotective gene Kruppel like factor 2 (KLF2) as well as 
decreased levels of expression of monocyte chemoattractant protein-1 (MCP1)20. In contrast, 
VECs located in the aortic side of the leaflets have a higher expression of proteins involved in 
calcification and ossification related processes21.  
1.2 AVS 
Several registries and epidemiological studies have shown a significant association between 
age and AVS prevalence, reaching a prevalence of 2 to 7% in individuals above 65 years of 
age22 and representing a substantial burden in the elderly population 23-25. When severe, AVS 
causes a significant cardiac outflow obstruction with a one-year mortality rate above 50% in 
severely symptomatic AVS patients26. 
The progressive aortic valve narrowing develops as a consequence of an increased thickening 
followed by calcification of the aortic valve leaflets1. A vast majority of pharmacological 
clinical trials have failed to stop or regress the disease27, leaving surgical and transcatheter 
aortic valve implantation (TAVI) as the only available therapeutic treatment28.   
The risk of AVS increases with age as well as other factors such as male gender 24, 
hypercholesterolemia24, hypertension24, obesity29 smoking30, renal dysfunction31, diabetes, 
metabolic syndrome32 and having a bicuspid aortic valve (BAV). BAV is a common congenital 
abnormality with a prevalence of 1-2% in the population33. Moreover, AVS often co-exists 
with coronary artery disease34. However, about 50% of patients with AVS do not have 
concomitant coronary artery disease35, indicating that this comorbidity is not completely 
overlapping. Differential mechanisms between the two cardiovascular diseases are further 
supported by the lack of effect of for example statins, which are world-leading drugs for 
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coronary artery disease treatment, but ineffective in slowing down AVS in large clinical trials36-
38. 
The morphological hallmark of AVS is, as mentioned previously, an increased thickening of 
the aortic valve leaflets with concomitant presence of calcified nodules which may extend 
throughout the whole surface of the aortic valve leaflets (Figure 3).  
 
Figure 3. Calcified aortic valve leaflet – calcification stained with Alizarin red. 
Calcification starts at the aortic side of the leaflets, primarily in the attachment points to the 
aortic wall as a result of being the regions exposed to the highest mechanical stress1. The 
presence of calcified nodules then expand towards the belly of the leaflets, disturbing the 
organized molecular and cellular cuspal micro-architecture39. It is interesting to mention that 
previous studies have shown different global transcriptional and protein expression signatures 
when comparing non-calcified and calcified regions of aortic valves from AVS patients40. As 
a consequence of the calcification process, the valve is not capable of the correct opening 
movement, producing the cardiac outflow obstruction characteristic of the disease. This may 
be accompanied by an impaired closing movement leading to aortic valve regurgitation. 
1.2.1 AVS diagnosis 
The evaluation of the aortic valve function for diagnosis of AVS is typically studied in the 
clinic by echocardiography41. This method enables the characterization of the blood 
hemodynamics in addition to mechanical parameters of the aortic valve, such as aortic valve 
area (AVA) and transaortic peak velocity, as well as left ventricular functionality42. The AVA, 
defined as the opening orifice area of the leaflets, corresponds to 3-4 cm2 in a healthy person 
and is accompanied by a transaortic peak velocity below 1 m/s. The 2017 European Society of 
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Cardiology (ESC) guidelines define severe AVS by an AVA under 1 cm2 and a transaortic 
peak velocity above 4 m/s accompanied by a mean pressure gradient, defined as the difference 
in blood pressure before and after the aortic valve, which is above 40 mm Hg when left 
ventricular ejection fraction (EF) is preserved43. It must be added that the progression of the 
disease varies in different patients. For this reason AVS patients are stratified into fast and slow 
progressors44. This is measured by the yearly increase in blood peak velocity, being fast 
progression when the increase is above or equal 0.3 m/s/year and slow progression when below 
0.3m/s/year43. 
1.2.2 Phases of AVS 
AVS progression can be divided into two independent phases where several factors such as 
lipid infiltration, inflammation and physicomechanical forces converge into end-stage 
calcification of the aortic valve. These two consecutive phases have been described in the 
literature as the initiation and propagation phase45-47. 
1.2.2.1 Initiation phase 
Low shear and high tensile stress give rise to the initiation phase of AVS by inducing a local 
VEC dysfunction in the aortic side of the aortic valve leaflets48. This leads to the infiltration of 
lipoproteins and apolipoproteins such as apolipoprotein B (ApoB)49 and lipoprotein (Lp) (a)50, 
51, from the bloodstream to the subendothelial space of the aortic valve48.  
This process is accompanied by a subsequent VEC activation characterized by the 
overexpression of adhesion molecules such as vascular cell adhesion molecule 1 (VCAM-1) 
and intracellular cell adhesion molecule 1 (ICAM-1), which leads to inflammatory cell 
infiltration52-55. The fact that these events occur at the aortic side of the aortic valve leaflets 
may explain why calcified nodules first appear and are more pronounced on the aortic side of 
the aortic valve leaflets. 
Increased oxidative stress is another hallmark of the initiation phase of AVS56. The increased 
oxidative stress in the aortic valve leaflets induces the formation of oxidized low density 
lipoproteins (oxLDL) and oxidized phospholipids which induce calcification in vascular 
cells57-59. In addition, oxLDL increases the expression of VCAM-1 and ICAM-1, thus further 
increasing the extravasation of immune cells from the vessel lumen into the aortic valve49, 53, 
60. Oxidized phospholipids can also be transformed by lipoprotein phospholipase A2 into 
lysophosphatidylcholine (LPC), which has been associated with increased apoptosis of VICs61. 
This has been further studied in mouse models demonstrating that an increased oxidative stress 
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induced by angiotensin II (Ang-II) leads to increased calcification in the aortic valve62. 
Interestingly, Ang-II is formed by the action of the angiotensin converting enzyme (ACE), 
which is upregulated in stenotic valves63.  
Morphological and cellular analyses of stenotic valves have shown an early infiltration of 
macrophages and other immune cells39, 64. Once in the subendothelial space, activated 
macrophages take up oxLDL and secrete pro-inflammatory cytokines as well as ECM 
degrading enzymes that may lead to the first macroscopic observations, such as increased aortic 
valve thickening and early mechanical dysfunction39. These observations have received 
support from studies where increased levels of proteolytic activity prior to the formation of 
calcification have been identified in early stages of AVS39. 
1.2.2.2 Propagation phase 
The impaired ECM formation and degradation, as a consequence of non-resolved local 
inflammation, can induce the generation of sites for extracellular dystrophic calcification65, 
defined as the deposition of calcium and phosphate crystals in soft tissues. Moreover, activated 
macrophages and VICs actively release calcifying extracellular vesicles (EVs). EVs are 
enriched with pro-calcifying factors such as tissue non-specific alkaline phosphatase (TNAP) 
and annexins66, 67 which facilitate the ion entrance into the vesicle, thus increasing the necessary 
components for the initiation of mineralization, which ultimately form hydroxyapatite crystals 
serving as initiation sites for further dystrophic mineralization68-70.  
In the following stages of AVS, the increased inflammation together with the dystrophic 
calcification further activate VICs and direct them into the myofibroblastic and osteoblastic-
like phenotypes71 through the upregulation of osteogenic pathways, promoting an active 
initiation of the aortic valve calcification process72. Indeed, mouse models with high levels of 
inflammation, such as apolipoprotein E-deficient (Apoe-/-) mice, have lipoprotein infiltration, 
immune cell infiltration and late-stage calcification in the aortic valve73. 
Myofibroblastic VIC differentiation further activates pathophysiologic pathways which 
increase the aberrant ECM deposition and degradation. This process occurs primarily at the 
aortic side of the leaflets (tunica fibrosa) where VICs may have a higher plasticity for 
differentiating into the cell subtypes mentioned above40. VIC myofibroblastic differentiation is 
characterized by an increased expression of α-smooth muscle actin (α-SMA) and vimentin74, 
75. VIC myofibroblastic differentiation induced by TGFβ76 promotes SMAD activation77, 78, 
which has been shown to increase GAG chain elongation. GAG chain elongation increases low 
density lipoprotein (LDL) binding to the ECM79. Moreover, during the propagation phase, 
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activated VICs together with activated macrophages and other immune cells will increase the 
release of MMPs and cysteine endoproteases, resulting in an aberrant disruption of the ECM 
fibers (collagen and elastin) which serve as a scaffold and substrate for dystrophic calcification 
nodules. 
In the last stages of AVS, oVICs are responsible for the heterotopic bone formation 
characteristic of the late stages of the calcification process of the aortic valve. oVICs are 
characterized by having an increased expression of the osteoblastic markers Runx280 and 
BMP218, 72. BMP2 plays an important role in the initiation of the osteoblastic differentiation 
whereas Runx2 is a master regulator of skeletal development and osteogenesis. BMP2 belongs 
to the TGFβ superfamily, which, through its receptor bone morphogenetic protein receptor type 
2 (BMPR2) induces the phosphorylation and activation of SMAD1/5/8, proteins that will 
further activate genes involved in the differentiation into osteoblastic-like cells such as Runx2, 
Osteopontin (OPN) and TNAP81, enzyme that promotes the conversion of the calcification 
inhibitor pyrophosphate (PPi) to free phosphate (Pi)82. Runx2 expression has been found in 
cells surrounding calcified particles in macroscopically healthy valves, linking its expression 
to an early osteoblastic differentiation of valvular cells83. Moreover, the role of Runx2 in 
osteoblastic differentiation has been shown in animal models, where calcification was inhibited 
after its genetic deletion84, demonstrating the importance of Runx2 in the calcification process. 
1.2.3 Genetic studies in AVS 
Several genetic studies have been performed in order to identify genes which play determinant 
roles in AVS. The lipoprotein (A) (LPA) locus, which encodes for Lp (a) was identified in a 
genome-wide association study (GWAS) to be associated with incident AVS and prevalent 
aortic valve calcium85. Furthermore, a transcriptome-wide association study (TWAS) 
identified a palmdelphin (PALMD) variant to be associated with AVS86. Finally, a variant in 
the fatty acid desaturase (FADS)1/2 locus has been associated with AVS and valvular 
calcification87, with accompanying changes in transcription and fatty acids locally in the aortic 
valve88. 
1.2.4 AVS treatment  
As mentioned before, there is no current pharmacological treatment to cure nor halt AVS. 
Traditionally, surgical aortic valve replacement has been the method used for these patients. 
However, during the last decade, TAVI has emerged as a less-invasive method for valve 
replacement. TAVI was initially considered for patients who were not suitable for traditional 
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valve replacement due to co-morbidities89, but is now expanding its indication to moderate and 
low risk patients.  
Randomized clinical trials testing the role of statins in patients with AVS have shown that 
reduction of LDL cholesterol does not alter echocardiographic parameters nor calcification 
measured by computer tomography (CT)36-38, despite the evidence that LDL cholesterol is 
associated with disease progression24. However, Lp (a) was found to be increased in patients 
treated with rosuvastatin90, suggesting that this increase may have masked any positive effect 
of the reduced LDL cholesterol. 
Due to the lack of effect of statins and their possible effect in increasing Lp (a), proprotein 
convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as potential and promising 
new candidates as a pharmacological treatment of AVS91, 92. Indeed, by increasing the levels 
of low density lipoprotein receptor (LDLr), PCSK9 inhibitors achieve a reduction in LDL 
cholesterol levels by more than 50%. Interestingly, and in contrast to the observations in statins, 
PCSK9 inhibitors also reduce the levels of Lp (a)93, 94. 
For this reason, a deeper understanding of the biological processes and molecular mechanisms 
underlying AVS is needed for the future development of novel pharmacological therapies. 
1.3 THE ARTERIAL WALL 
The arterial wall is organized in three different layers: the tunica intima, media and adventitia95. 
The tunica intima is the innermost layer and is in direct contact with the blood flow. Formed 
by a thin monolayer of vascular endothelial cells, this layer is responsible for immune cell 
recruitment by the surface protein expression of adhesion molecules. The tunica media is 
mainly composed by elastin fibers and vascular smooth muscle cells (VSMCs).  
VSMCs are responsible for maintaining the contractile tone of the arteries, and can be divided 
into two groups based on their phenotype. The contractile phenotype is characterized by a high 
presence of α-SMA and myosin heavy chain 11 (MYH11), as well as a limited proliferation 
rate. On the other hand, the synthetic phenotype is characterized by less contractile ability and 
increased proliferation and migration, as wells as increased MMP secretion and collagen 
production96. Under certain conditions, other VSMC subtypes have been identified, for 
example the osteoblastic phenotype, which in similarity to oVICs are characterized by 




The tunica adventitia, being the outermost layer, is mainly composed of connective tissue, 
adipose cells and fibroblasts. This layer is responsible for providing physical support to the 
vasculature (Figure 4). 
 
Figure 4. Schematic representation of the different layers of the arterial wall. 
1.3.1 Vascular injury and intimal hyperplasia 
Intimal hyperplasia is a reparative process within the arterial wall as a response to a 
hemodynamic or mechanical injury. The primary pathology of intimal hyperplasia is 
characterized by the migration of VSMCs from the media layer into the subendothelial space 
of the artery, accompanied by an increased VSMC proliferation99, which ultimately leads to 
stenosis and occlusion of the vessel (Figure 5). 
 
Figure 5. Schematic representation of intimal hyperplasia in the arterial wall. 
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After vascular injury, for example a coronary artery bypass graft (CABG) failure or in stent 
placement after coronary intervention, leukocytes attach to the endothelium and infiltrate the 
arterial wall. This leads to the secretion of pro-inflammatory molecules and ECM degrading 
enzymes, as well as growth factors that further increase the response by locally recruiting more 
leukocytes to the site of injury100 and modulating VSMC behavior into the synthetic phenotype, 
thus inducing activation, migration and proliferation.  
The newly formed intima layer, also named neointima, is characterized by the presence of 
VSMCs positive for α-SMA, and fibroblasts, accompanied by an aberrant ECM deposition101, 
102. Moreover, immunohistochemical evaluation of intimal hyperplasia injury sites has 
identified an increased presence of neutrophils, lymphocytes and macrophages103, as well as 
cytokines and MMP secretion104. Despite the pronounced thickening of the arterial wall by the 
newly formed intima layer, the tunica media remains thin with no apparent changes in 
morphology nor cell composition105. 
Currently, treatment for intimal hyperplasia relies on the effectiveness of drug eluting stents 
for the prevention of restenosis after percutaneous coronary interventions. Stents are coated 
with cell cycle inhibitors such as rapamycin and paclitaxel, therefore blocking VSMC 
proliferation. However, intimal hyperplasia still remains a clinical problem in surgical 
procedures, for example in CABG failure106. 
1.4 ATHEROSCLEROSIS 
Atherosclerosis is the underlying cause of coronary artery disease107 whereas cerebrovascular 
atherosclerosis is one of the causes of stroke. In similarity to AVS, atherosclerosis is an 
inflammatory disease characterized by the early infiltration and deposition of cholesterol-
containing LDL within the vascular wall followed by a pronounced infiltration of inflammatory 
cells108. 
The initiation of the atherosclerotic plaque starts with the infiltration of cholesterol-containing 
LDL in the vascular wall through the intima109. The LDL particles located in the subendothelial 
space are subjected to oxidation by the action of myeloperoxidase, lipoxygenase, and reactive 
oxygen species110. The accumulation of oxLDL particles in the subendothelial space leads to 
the subsequent activation of the endothelial cells, whereby the expression of adhesion 
molecules such as VCAM-1 is increased111. As a response, circulating monocytes are recruited 
to these sites. Once in the subendothelial space, monocytes differentiate into macrophages and 
start phagocyting oxLDL particles112. The unending engulfment of oxidized particles leads 
macrophages to produce more inflammatory cytokines which results in an increased 
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recruitment of more macrophages and other inflammatory cells. Activated macrophages 
differentiate into foam cells which stay trapped in the subendothelial space, leading to the 
characteristic chronic inflammation process of this disease113 that drives the formation and 
maturation of the atherosclerotic plaque.  
Moreover, dendritic cells take up antigens in the plaque and migrate to secondary lymphoid 
organs in the vicinity where they present the antigens to naïve T-cells through MHC class II 
antigen presentation. T-cells differentiate into several subtypes, which play different roles in 
the development of the atherosclerotic plaque. Furthermore, the presence of anti-oxLDL 
antibodies has been detected in atherosclerotic plaques, demonstrating the role of B-cells in 
mediating responses against atherosclerosis plaque114. Indeed, vaccination targeting oxLDL 
exerts a beneficial effect against atherosclerosis in preclinical animal models115, 116.  
The presence of dead cells forming necrotic areas is characteristic of advanced atherosclerotic 
lesions117. The accumulation of dead cells is the result of the combination of both increased 
apoptosis and a reduced efferocytosis, the latter meaning clearance of the apoptotic cells 118. 
Advanced atherosclerotic plaques are also characterized by increased calcification, which is as 
an independent predictor of cardiovascular mortality66, 119, 120, specifically plaques with 
increased microcalcifications. Indeed, atherosclerotic plaque microcalcifications have been 
proposed to play a critical role in plaque stability and to be a risk factor for plaque rupture 
compared with large and well-established calcifications121, 122.  
The formation of calcified nodules within the atherosclerotic plaque resembles those observed 
in aortic valves described above, by means of impaired ECM deposition, generation of sites for 
dystrophic mineralization, EVs released by macrophages and VSMC which ultimately form 
hydroxyapatite crystals123, and VSMC differentiation into osteoblastic-like cells. 
A stable fibrous cap consisting of VSMCs and collagen covers the atherosclerotic plaque 
keeping it isolated from the bloodstream and protected from rupture. Though the triggers are 
not fully understood, local breakdown of the collagen fibers by the action of MMPs together 
with VSMC death and increased calcification promote the weakening and subsequent rupture 
of the fibrous cap124, or alternatively atherosclerotic plaque erosion which is defined as the 
absence of endothelium leading to acute thrombus formation without signs of plaque rupture125. 
In the case of plaque rupture, the inner content of the atherosclerotic plaque is released into the 
vessel lumen, which interacts with the bloodstream, inducing local platelet aggregation and a 
subsequent thrombus formation124, 126. The thrombus may lead to coronary artery occlusion, 
causing myocardial infarction, or stroke if this happens in a cerebrovascular artery.  
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1.4.1 Atherosclerosis treatment 
Currently, pharmacological intervention for atherosclerosis management relies on lipid 
management by statins127. Despite the clear effect of statins in reducing inflammation128, 
evidence suggests that their beneficial effects rest primarily in their potential to reduce lipids 
rather than in targeting inflammation.  
Targeting inflammation as an option for reducing cardiovascular risk has been widely studied, 
and was recently highlighted by a clinical trial that demonstrated that directly targeting 
inflammation may serve as a potential treatment for cardiovascular risk reduction129. The study 
involved patients with a history of myocardial infarction, and the results showed that the risk 
of recurrent cardiovascular events was lower among those who received anti -inflammatory 
therapy by the interleukin (IL) 1β monoclonal antibody (Canakinumab) compared to patients 
that received placebo. However, one of the adverse effects of this therapy was that patients 
were more prone to infections due to neutropenia and had significantly more deaths due to 
infection or sepsis.  
Another recent clinical trial has also shown that patients with chronic coronary disease 
receiving a low-dose of colchicine, an anti-inflammatory drug, had a significantly reduced 
cardiovascular risk compared with placebo treated patients130, supporting the beneficial effects 
of targeting inflammation in atherosclerosis. However, this approach is not yet implemented in 
clinical therapy for patient management. Moreover, recent evidence has shown that high levels 
of the omega-3 polyunsaturated fatty acid (n-3 PUFA) eicosapentaenoic acid (EPA) 
significantly decreases ischemic events, including cardiovascular death131. This observation 
will be discussed in more detail in the coming chapters of this thesis. 
In advanced coronary atherosclerotic disease and in acute coronary syndromes, either CABG 
or percutaneous coronary intervention (PCI) with stent implantation is used when the 
atherosclerotic plaque causes a significant vessel obstruction or after plaque rupture. 
1.5 MOLECULAR MECHANISMS OF CARDIOVASCULAR CALCIFICATION 
Several molecular mechanisms take place during the mineralization process in cardiovascular 
diseases. Most of these molecular mechanisms are common to all types of cardiovascular 
calcification. For this reason, the following section applies to both aortic valve calcification 
and atherosclerotic plaque calcification. 
During embryo bone development, secreted Wnt binds to the LDL co-receptor Lpr5132. This 
activates β-catenin that translocates to the cell nucleus, activating bone-formation related genes 
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expression. Experimental studies have identified a high expression of Wnt in human and 
murine atherosclerotic plaques133, as well as elevated levels of Lpr5, β-catenin and Wnt3a 
ligand in valves of AVS patients compared with non-calcified valves, suggesting a reactivation 
of the Wnt/β-catenin pathway134. 
Notch1, 2, 3 and 4 are transmembrane receptors that play a crucial role in the regulation of 
ossification processes. Notch pathways suppress Wnt/β-catenin signaling. Specifically, the 
intracellular domain of Notch1 binds directly to β-catenin, suppressing the expression of Runx2 
and as a consequence the ossification process135. Indeed, mutations in Notch1 have been 
described to be associated with AVS136, and Notch1 overexpression reduces osteoblastogenesis 
by suppressing Wnt signaling135. 
Under homeostasis, the pro-calcification molecular pathways in the vasculature are repressed 
by the action of calcification inhibitors. Within this family, some of the most important 
inhibitors are Matrix gla protein (MGP), Klotho, Osteoprotegerin (OPG) and PPi.  
MGP is produced locally by structural cells and its function depends of the carboxylation of 
the protein glutamate residues by vitamin K. Indeed, patients treated with vitamin K antagonists 
develop higher coronary and valvular calcification137, 138. Furthermore, MPG has been shown 
to be decreased in human calcified valves from AVS patients compared with non-calcified 
valves139. This has been further observed in murine models where deletion of MGP induces 
cardiovascular calcification. When MGP is carboxylated, it actively inhibits calcification by 
directly binding to BMP or to free calcium ions140. Mechanistically, in vivo studies in rats have 
shown that warfarin treatment promotes cardiovascular calcification by inhibiting the recycling 
of vitamin-K, thus suppressing the subsequent carboxylation of MGP141. As a matter of fact, 
warfarin administration in rats is a commonly used model for cardiovascular calcification142, 
143.  
Klotho is a transmembrane protein which acts as a co-receptor for fibroblast growth factor 23 
(FGF23)144. FGF23 signaling through the heterodimer Klotho and FGF receptor decreases 
phosphate resorption via down-regulation of the protein levels of the renal proximal tubule 
type-II sodium phosphate co-transporters as well as 1,25(OH)2 vitamin D synthesis. Moreover, 
Klotho can be also present in soluble form in circulation. The functions of soluble Klotho have 
been associated with Wnt signaling inhibition145, as well as with promoting endothelial 
integrity in the vasculature146. 
Furthermore, OPG plays a role in inhibiting cardiovascular calcification by acting as a decoy 
receptor for the receptor activator of nuclear factor-kappa B (NFκB) ligand (RANKL)147. In 
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the absence of OPG, RANKL binds to the transmembrane receptor RANK and intracellularly 
signals the expression of osteogenic gene circuits.  
PPi is derived from the hydrolysis of ATP by the action of the ectonucleotide 
pyrophosphatase/phosphodiesterase 1 (eNPP1). PPi inhibits mineralization by substituting 
phosphate (Pi) in the calcified nodule148. Loss of function of eNPP1 has been associated with 
generalized arterial calcification in infants149. Moreover, preclinical studies have shown that 
eNPP1 deletion reduces atherosclerotic plaque calcification150. On the other hand, in 
extracellular fluids, TNAP is the enzyme in charge of limiting the availability of PPi by 
hydrolyzing it into Pi151, promoting the deposition and growth of phosphate crystals152 
(Figure 6). TNAP activity is tightly controlled by macrophages, which under certain 
conditions mediate anti-calcifying actions  by downregulating its expression153. Furthermore, 
TNAP overexpression increases medial calcification in ex vivo vascular models154. Specific 
endothelial overexpression of TNAP has also been shown to increase vascular 
calcification155. 
 
Figure 6.  Schematic representation of the opposing functions of eNPP1 and TNAP in the process of calcification 
deposition. 
1.6 CALCIFICATION DETECTION 
Several methodologies can be used in order to study the presence of calcification both in 
atherosclerotic plaques as well as in aortic valves from patients with AVS.  
As mentioned before, echocardiography is the first-line evaluation method for assessing the 
severity of AVS. However, resting echocardiographic assessment of AVS patients may be 
discordant, especially in the elderly population156, giving rise to medical uncertainties157. For 
this reason, the interest in calcification assessment of the aortic valves of those patients has 
increased in the last years. 
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Computed tomography (CT) is a widely used method for the study of calcification in 
cardiovascular diseases. Indeed, CT calcium scoring of the coronary arteries has become a 
well-established method for coronary artery calcium (CAC) volume content and density 
evaluation in atherosclerotic plaques, which currently serves as a powerful predictor of adverse 
clinical events158, 159. Aside from being used in patients with atherosclerosis, CT has also 
emerged as a method for the study of aortic valve calcium in patients with AVS. Several studies 
have confirmed the linear correlation between CT results and calcium content from explanted 
valves, suggesting this method is a powerful tool for aortic valve calcium quantification in AVS 
patients160, 161. 
For this reason, CT in aortic valves has emerged as a potential  complementary tool to 
echocardiography for AVS severity assessment due to its independence of hemodynamic 
patient status. Using CT in AVS patients is part of the recommendations in the latest ESC 
guidelines for the management of valvular heart disease43. However, it ought to be mentioned 
that one of the limitations of CT in AVS patients is that it ignores the presence of non-calcific 
leaflet thickening, mostly a consequence of pro-fibrotic events, which also significantly 
contributes to the pathology and progression of AVS, especially in women 162. 
CAC scoring by CT provides information on atherosclerotic plaques for risk prediction of 
future cardiovascular events. Despite the fact that CAC volume measurement of atherosclerotic 
plaques provides a direct association with cardiovascular events163, CAC density inversely 
correlates with the same outcome, suggesting that a low CAC density (characteristic of 
microcalcifications) is a potential risk factor for cardiovascular events resulting from 
atherosclerotic plaque rupture164. 
1.7 N-3 PUFA AND THE RESOLUTION OF INFLAMMATION  
The infiltration of lipids, lipoproteins and inflammatory cells are hallmarks of the chronic 
inflammatory process in cardiovascular diseases. Importantly, cardiovascular inflammation is 
characterized by a failure in the resolution of the inflammation process. The resolution of 
inflammation is an active, well-orchestrated process that actively stops and resolves the 
inflammatory response, decreasing leucocyte recruitment and promoting efferocytosis165, 166. 
Resolution of inflammation is driven mainly by macrophages and other immune cells. 
However, structural cells also play an important function throughout the process.  
When an insult occurs, the inflammation/resolution response is divided into two phases. The 
first phase is the initiation of the inflammation, characterized by the infiltration of immune cells 
into the damaged or infected area, followed by an increased production of pro-inflammatory 
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molecules such as the pro-inflammatory lipid mediators leukotrienes (LTs) and prostaglandins 
derived from the n-6 PUFA arachidonic acid (AA) 64. In the second phase, the resolution of 
inflammation phase takes over to halt the inflammatory process and bring the system to 
homeostasis in an active manner. The resolution of inflammation is mediated by several 
molecules such as IL-10, annexin A1167, nitric oxide, hydrogen sulfide168, carbon monoxide169, 
and with particular importance for this thesis, by specialized pro-resolving lipid mediators 
(SPMs)170. Derived from long chain PUFA, mostly n-3 PUFA, SPMs signal through specific 
cellular G protein-coupled receptors (GPCRs) 171. If these signaling circuits fail, inflammation 
will not resolve and damage will persist and chronify165.  
By the action of the cyclooxygenase and lipoxygenase metabolism, n-3 PUFA-derived SPMs 
are enzymatically metabolized into the SPM-resolvin, maresin and protectin families which 
have the potential of initiating the resolution phase, importantly without inducing 
immunosupression171.  
Specifically, n-3 PUFA serve as a substrate for the generation of the docosahexaenoic acid 
(DHA)-derived D- series resolvins (RvD), maresins (Mar) and protectins  as well as the EPA-
derived E-series resolvins (RvE)102 (Figure 7). 
 
Figure 7. SPMs derived from the n-3 PUFA EPA and DHA. 
A fine balance between the pro-inflammatory lipid mediators derived from n-6 PUFA and the 
SPMs derived from n-3 PUFA may be decisive for disease outcome. For example, the 
LTB4/RvD1 ratio is higher in vulnerable regions of human atherosclerotic plaques, being those 
more prone to rupture172.  
As mentioned before, the implication of n-3 PUFA as a possible treatment for cardiovascular 
inflammation has been explored during the last years. However, n-3 PUFA treatment for 
cardiovascular risk reduction has been controversial. Indeed, despite a clinical trial showing 
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that 1 g/day dietary supplementation of n-3 PUFA led to a clinically important significant 
benefit in reducing cardiovascular risk173, other clinical trials testing low concentrations of n-3 
PUFA (≤1 g/day) have not revealed protective effects when compared with placebo174-176.  
However, another clinical trial using a higher dose of pure EPA (1.8 g/day) combined with 
statin therapy in patients with hypercholesterolemia revealed that the risk of ischemic events 
was significantly lower in the EPA treated group compared with placebo177. Furthermore, the 
beneficial effects of higher doses of pure EPA (4 g/day) in cardiovascular disease prevention 
have been recently explored in another large randomized controlled clinical trial, demonstrating 
that EPA treatment in patients already receiving statin therapy conferred a 25% relative risk 
reduction in major cardiovascular events compared with placebo131. Interestingly, another 
recent study has shown that EPA treatment (4 g/day) slowed atherosclerotic plaque progression 
and induced plaque regression178. These results therefore point to a dominant role of EPA, and 
not DHA, in reducing cardiovascular risk.  
Moreover, other studies have shown that higher levels of C-reactive protein (CRP) in coronary 
artery disease are associated with a lower intake of n-3 PUFA as well as a lower n-3 PUFA/n-
6 PUFA ratio179. This observation has also been replicated in healthy volunteers with a high n-
6 PUFA/n-3 PUFA ratio intake, who have been shown to have increased CRP levels and 
elevated inflammatory markers180. These observations may reflect a potential imbalance 





Figure 8. Potential impact of dietary intake of n-3 and n-6 PUFA. Blue color stands for predominant pro-resolution 
of inflammation. Red color stands for predominant pro-inflammation. Reproduced from Artiach et al., Kardiol 
Pol. (2020)181. 
1.7.1 RvE1 and ChemR23 in cardiovascular inflammation 
SPMs exert their actions through specific GPCRs. Specifically, ChemR23 and BLT1 serve as 
receptors for RvE1; FPR2/ALX and GPR32 for RvD1 and RvD3; and GPR18 for RvD2165, 182 
(Figure 9).  
 
Figure 9. Specific GPCRs for RvE1 and for the D-series RvD1, RvD2 and RvD3. 
ChemR23 is a GPCR coupled to Gi/o, which leads to inhibition of adenylyl cyclase followed 
by cAMP accumulation, intracellular calcium release, and subsequent phosphorylation of 
mitogen-activated protein kinases (MAPK) 183, 184. ChemR23 has been identified in several cell 
types including macrophages185, dendritic cells186, natural killer cells187 as well as 
chondrocytes188, osteoblasts189, endothelial cells190 and VSMCs191. Although ChemR23 was 
originally described as one of the receptors for chemerin183, subsequent studies identified 
ChemR23 as also having a similar affinity for RvE1192. 
Chemerin is a chemoattractant protein for M1 macrophages193 mainly found in adipose tissue 
and associated with several diseases such as chronic kidney disease (CKD) and diabetes. 
Chemerin levels have also been shown to be increased in coronary artery disease patients not 
taking low dose aspirin194. Moreover, increased chemerin levels increase blood pressure in 
mice195. However, other studies have shown that chemerin exerts opposite biological functions. 
For example, chemerin levels in CKD patients have been associated with lower coronary 
calcium196, as well as with survival in patients receiving dialysis197. Interestingly, chemerin-




RvE1 promotes M2 macrophage polarization characterized by the increased expression of 
arginase 1 (Arg1), Cluster of differentiation (CD) 206, CD163 and CD36 and their anti-
inflammatory actions198. Recent studies from our group and others have described that RvE1 
protects against atherosclerosis development and VSMC calcification102.  
In atherosclerosis, RvE1 modifies macrophage behavior through ChemR23199 as well as 
reduces atherosclerotic plaque development200. In addition, the genetic deletion of ChemR23 
increases atherosclerotic plaque size and inflammation in Apoe-/- mice199.  
In the context of intimal hyperplasia, RvE1 treatment actively promotes M2 macrophage 
polarization, reducing neointima formation after arterial injury in animal models198, 201. 
Moreover, Pi-induced VSMCs calcification is reduced after RvE1 treatment via ChemR23 
signaling202, pointing to the RvE1/ChemR23 axis as a key disrupted pathway in the 
development of cardiovascular diseases. 
1.7.2 RvE1 and ChemR23 in cardiovascular calcification 
As mentioned previously, macrophages are key drivers of the process of cardiovascular 
calcification. Indeed, extracellular Pi supplementation induces, as a counter response, the 
generation of a specific subset of macrophages with anti-calcifying properties, characterized 
by a decreased gene expression and protein activity of TNAP, and accompanied by a sharp 
increase in gene expression of the M2 marker Arg1 and of the anti-calcifying ectoenzyme 
eNPP1. Interestingly, the latter changes induced by Pi supplementation were accompanied by 
a sharp induction of ChemR23 expression (6.1-fold) 153, 203, suggesting that ChemR23 could 
play an important role in anti-calcifying macrophages. This is explored in more detail later in 
the present thesis. 
SPMs derived from n-3 PUFA may have an important translational implication from a 
therapeutic point of view for cardiovascular calcification. Previous human studies have shown 
that higher n-3 PUFA serum levels are associated with a lower incidence of coronary artery 
calcification204. In line with this, experimental in vivo studies have shown that EPA 
administration in rats prevents macrophage infiltration as well as warfarin-induced vascular 
calcification by suppressing MMP9 activity205. Experimental studies from other laboratories 
have shown that supplementation with EPA also suppresses Wnt signaling, decreasing BMP4 
and AXIN2, while upregulating Klotho mRNA levels in mice206.  Moreover, Klotho-/- mice 
upregulate the endogenous levels of RvE1 after EPA supplementation and decrease calcium 
volume scores in thoracic and in abdominal aortas assessed by micro CT207. 
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Little is known about EPA and its downstream molecule RvE1 in the development of 
inflammation-dependent cardiovascular calcification. For this reason, understanding the role 
of RvE1 as well as ChemR23 in the interplay between structural and inflammatory cells in 
cardiovascular calcification is therefore needed. This may open up new opportunities for the 
development of novel therapies for inflammation-dependent cardiovascular diseases in which 























The studies included in this thesis aimed to unravel the role of ChemR23 in cardiovascular 
inflammation.  
The specific aims were:  
I. To elucidate the role of the n-3 PUFA/RvE1/ChemR23 signaling axis in the 
development of AVS (Article I). 
II. To determine the role of n-3 PUFA and ChemR23 in the development of intimal 
hyperplasia (Article II). 
III. To establish the role of n-3 PUFA and the derived SPM RvE1 signaling through 




3 EXPERIMENTAL METHODOLOGY 
3.1 AVS – HUMAN AORTIC VALVES 
Tricuspid aortic valves from AVS patients undergoing aortic valve replacement at Karolinska 
University Hospital (Solna, Sweden) were collected. The study presented in the current thesis 
using this material was approved by the local ethics committee (2012/1633) and was in 
agreement with the Declaration of Helsinki. All patients gave informed consent.  
Macroscopic evaluation of the aortic valves allowed us to visually identify and further dissect 
non-calcified and calcified regions. This approach allowed us to establish a model of the 
disease continuum within each individual, going from the healthy or fibrotic initial stage (non-
calcified tissue) to the advance stage characterized by the presence of bone nodules.   
In the experiments presented in current thesis, valve tissue was used for gas chromatography, 
liquid chromatography tandem mass spectrometry (LC-MS/MS), or for transcriptomic analysis 
using Gene Chip Affymetrix human transcriptome 2.0. Aortic valve leaflets were also used for 
immunohistochemical analysis. 
3.2 AVS – IN VIVO MODELS 
In order to understand the biological and molecular mechanisms that drive human AVS, animal 
models of the disease are needed. Some large animals, such as swine, can develop AVS 
similarly to humans208. However, conducting research in large species is time-consuming and 
costly, thus leaving them as inefficient models for the study of the disease. For this reason, 
mouse models are currently the most widely used in vivo models for AVS due to their low cost 
and easy management as well as the existence of a wide variety of genetically modified strains.  
Ideally, AVS in mouse models should resemble the pathological hallmarks observed in humans  
to a certain degree. For example increased leaflet thickness, presence of calcification and 
inflammatory cell infiltration such as macrophages, together with endothelial activation as well 
as impaired ECM deposition. Moreover, AVS in mice should also mimic the hemodynamic 
characteristics of human AVS by means of increased transaortic valve peak velocity as well as 
decreased cusp separation or distance in systole. 
3.2.1 Hypercholesterolemic mouse models 
Different AVS models have been developed and used throughout the last decades for AVS 
research. Aged hypercholesterolemic mice, which are also used to model human 
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atherosclerosis, are widely used for AVS modeling since these mice mirror the age-associated 
AVS progression observed in humans209, 210.  
Apoe-/- mice have been described to develop AVS at advanced ages both with and without 
supplementation with a high-fat diet39, 73. However, Apoe-/- mice develop AVS faster when fed 
a high fat diet compared with mice fed chow diet. Similar to the human disease, this model 
develops an impaired aortic valve opening, observed by an increased transaortic peak velocity, 
associated with age. These mice also develop an increased valve thickening with concomitant 
presence of calcification, as well as immune cell infiltration in terms of macrophages211 
together with endothelial activation observed by increased VCAM-139, 73. Furthermore, Apoe-
/- mice express early changes related with AVS progression and prior to calcification, for 
example, increased levels of calcification-related proteins such as osteocalcin, Runx2 and 
TNAP as well as proteolytic activity212. 
Low density lipoprotein receptor-deficient/Apolipoprotein B-100-only (Ldlr-/-/ApoB100/100) 
mice also develop AVS in late stages of their lives58, 62. Ldlr-/-/ApoB100/100 mice, as well as 
Apoe-/- mice, develop lipid deposition in the aortic valve leaflets, accompanied by monocyte 
infiltration and calcification. Interestingly, Ldlr-/-/ApoB100/100 mice develop AVS in younger 
stages of life compared with Apoe-/- mice even without being fed a high-fat diet. 
Moreover, Ldlr-/- mice fed a high fat diet develop increased valve thickening and early markers 
of calcification. However, there is no current evidence of hemodynamically significant stenosis 
in these mice213-215.  
3.2.2 Non-hypercholesterolemic mouse models 
Notch1-/+ mice fed a high fat diet have been used to study aortic valve calcification processes. 
However, they do not develop AVS hemodynamically216. Interestingly, these mice are reported 
to be born with a BAV associated with concomitant aortic valve malformations. 
MGP-/- and Klotho-/- mice have been widely studied in the context of vascular calcification. 
Klotho-/- mice develop aortic valve calcification217, 218. There is no current evidence 
demonstrating the presence of aortic valve calcification in MGP-/- mice219. 
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In 2014 a new model of AVS was described induced by a mechanical injury to the aortic valve 
using a spring wire. The valve injury was performed by inserting the wire through the right 
carotid artery into the left ventricle, followed by moving the wire manually in and out 20 times 
and rotating it 50 times while monitored by echocardiography in B-mode (Figure 10). 
Interestingly, these mice started developing hemodynamical changes 1 week after injury, as 
well as increased thickening, immune cell infiltration, calcification and hemodynamically 
significant changes after 16 weeks of injury220, 221.  
 
Figure 10. Mouse aortic valve wire injury procedure. Representative B-mode echocardiographic images. (Left) 
Left ventricle with no wire insertion. (Middle) Wire at the aortic valve level. (Right) Wire inserted in the left 
ventricle. Arrow indicates wire. 
In the current thesis Apoe-/- mice fed a chow diet as well as the aortic valve wire injury model 
were used to put the results in both a hyperlipidemic and a non- hyperlipidemic context.  
3.2.3 Mouse echocardiography 
High-resolution echocardiography is currently the pillar technique for in vivo evaluation and 
assessment of aortic valve function in mice222. The fact that this method is a non-injurious and 
non-invasive technique, combined with the low degree of sedation needed, facilitates its use 
for longitudinal studies where multiple measurements are needed in each individual  animal. 
Mouse echocardiography makes it possible to obtain information on disease severity, valve 
morphology, leaflet calcification and valve functional performance. By using Doppler 
measurements, the transaortic peak velocity and the transvalvular pressure gradients can be 
assessed. Moreover, the B-mode (or 2D-mode) and M-mode (or 1D-mode) allows to study 
cusp separation at each heartbeat as well as changes in the left ventricular structure and 
function. However, the evaluation of changes in cusp separation requires an extensive training 
of the investigator and a large sample size in order to achieve reliable results and statistical 
power between groups209. 
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3.2.4 Mouse aortic valve morphological analysis 
As mentioned before, two of the hallmarks of AVS are the increased aortic valve leaflet 
thickness and increased calcification. In order analyze those parameters in mice, the aortic 
valve is sectioned from the first millimeter of the aortic root.  Aortic valve leaflet thickness is 
studied  as the average of the maximal thickness of each available cusps in all collected levels 
as previously described223. Similarly, the average of the area of each available leaflet is 
calculated at each collected level.  
Leaflet calcification is measured by Alizarin red staining. This method is further discussed in 
the following sections of this chapter. 
3.3 INTIMAL HYPERPLASIA – IN VIVO MODELS 
Two mouse models of intimal hyperplasia have been described in order to investigate the 
pathophysiological features of intimal hyperplasia. The one used in the current thesis, is 
generated by a permanent carotid ligation. The other, by endothelial denudation through 
mechanical injury to the vessel wall.  
The carotid ligation model is mostly performed in the left carotid artery by a complete ligation 
in the proximity of the bifurcation224, 225. This induces a complete obstruction of the blood flow 
and the formation of a thrombus which activates the endothelial layer. The neointima layer, 
which develops as a consequence of the ligation after 2 to 4 weeks post-surgery, is 
characterized, inflammatory cell infiltration and VSMC proliferation leading to complete 
occlusion of the vessel lumen distal to the ligation. One of the advantages of this model is the 
high reproducibility due to the lack of complex surgical manipulations. However, this model 
does not mimic in its totality the complications observed in the clinic after for example CABG 
failure. As an alternative, a partial ligation of the carotid artery can be performed thus avoiding 
the complete occlusion of the vessel lumen in order to resemble to a larger extent the clinical 
complication226.  
The endothelial denudation method for intimal hyperplasia is performed by passing a spring 
wire through the carotid or femoral artery three times227, 228. The damage to the endothelial 
layer induces the formation of a monolayer of platelets at the site of injury followed by a 
subsequent activation of the VSMCs, which leads to the formation of a neointima layer within 
2 weeks after injury. This method resembles in a higher extent the observed complications in 
a clinical set, however, high technical expertise is required as well as a large sample size in 
order to avoid high variability and perform consistent measurements.  
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Other methods to induce intimal hyperplasia, for example by a balloon injury, are done in other 
species such as rats229 or rabbits229. However, due to the size of the available balloons, those 
techniques are not an alternative in small rodents.  
3.4 ATHEROSCLEROSIS – IN VIVO MODELS 
Since wild-type (WT) mice are resistant to develop atherosclerosis, genetically modified 
hyperlipidemic mouse models are used for the study of this disease. The most common and 
widely used models are the Ldlr-/- 230 and the Apoe-/- mice231, 232, the latter used in this thesis.  
LDLr is primarily expressed in hepatocytes and functions by binding to the ApoE and ApoB-
100 in the circulating LDL and intermediate density lipoprotein (IDL), thus promoting its 
immediate clearance from the circulation. In Ldlr-/- as well as in Apoe-/- mice, the disruption of 
the cholesterol metabolism induces an increased and sustained level of circulating cholesterol 
which initiates the atherosclerotic plaque formation233. Interestingly, Ldlr-/- mice develop 
atherosclerotic plaques only when fed a high fat diet, however, Apoe -/- mice develop 
atherosclerosis without the need of high fat diet supplementation.  
Despite the differences in lipid profile between Apoe-/- mice and atherosclerosis patients, it is 
important to mention that the atherosclerotic plaques in Apoe-/- mice resemble in a high extent 
to human atherosclerotic plaques by means of having lipid accumulation, inflammatory cell 
infiltration, a fibrous cap rich in VSMC, necrotic cores and importantly for this thesis, plaque 
calcification in mature stages234. 
3.5 CALCIFICATION AND CELL PROLIFERATION 
3.5.1 Calcification 
In vitro models are used in order to elucidate the biological actions and molecular mechanisms 
of pharmacological interventions in the context of vascular and valvular calcification and cell 
proliferation. In the experiments presented in this thesis, VIC calcification was induced by a 
high Pi supplementation (2.6 mM) during 9 days202. Pi binds with the calcium present in the 
medium and precipitates into calcium phosphates. However, this precipitation is actively 
inhibited by the action of the calcification inhibitors secreted by the VICs. Nevertheless, when 
Pi is increased by external supplementation precipitation of calcium-phosphate crystals will 
occur, thus activating VIC osteogenic programs promoting the differentiation into oVICs. This 




In this thesis the WST-1 reagent was used in order to study cell proliferation. WST-1 is a stable 
tetrazolium salt which is cleaved to a soluble formazan molecule (dye) by the action of 
succinate-tetrazolium reductase, an enzyme that is part of the respiratory chain of the 
mitochondria, and only functions in metabolic active cells. The formazan molecule product of 
the reaction has a purple color which can be quantified by spectroscopy and correlated with the 
amount of alive cells.  
3.6 QUANTIFICATION OF CALCIFICATION AND LIPID DEPOSITION 
3.6.1 Calcification 
In order to detect and quantify calcification in cardiovascular diseases several methods are 
available. The Alizarin red staining is based on an anthroquinone dye that binds to the present 
calcium ions in the sample, providing an intense red color. This method can be used to assess 
calcification both in histological sections as well as in in vitro systems. Another calcification 
staining that is widely used is the Von Kossa staining, in which silver ions bind to phosphate 
in an acidic environment and provide a characteristic black color. Despite being commonly 
used for assessing calcification in for example atherosclerotic plaques236, Von Kossa staining 
should be used with care when studying calcification in tissues from mice on a C57/BL6 
background, due to the local presence of black melanocytes within the for example the aortic 
valve leaflets that can give rise to erroneous measurements. For this reason, in the experiments 
presented in this thesis only Alizarin red staining was used for assessing calcification in 
histological sections, both in aortic valves and atherosclerotic plaques. 
To study in vitro calcification, other methods apart from the previously described can be used. 
For example, using the Osteoimage mineralization assay, method that specifically detects 
hydroxyapatite crystals with a fluorescent label, which can be quantified by fluorescence 
intensity detection. 
3.6.2 Lipid deposition 
Due to the nature of the atherosclerotic plaque composition, lipid deposition is commonly 
measured to assess plaque size. This is studied by staining histological sections of the proximal 
part of the aortic root with Oil Red O (ORO). ORO stains lipids with a bright red color. This 
method can be used either in tissue sections as well as in in vitro systems. 
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3.7 FATTY ACIDS AND LIPID MEDIATORS ANALYSIS 
Several methodologies have been used in the experiments presented in this thesis in order to 
characterize the presence of different PUFA as well as lipid mediators in aortic valves and 
atherosclerotic plaques. Gas chromatography was performed for fatty acid analysis, 
specifically to explore the presence of n-6 and n-3 PUFA in human aortic valves as well as 
mouse myocardial tissue. Moreover, time-of-flight secondary ion mass spectrometry (TOF-
SIMS), a method that provides molecular information of solid sample surfaces at spatial 
resolutions down to the sub-micrometer regime237, was used for fatty acid profiling in mouse 
aortic valves, mouse atherosclerotic plaques as well as mouse myocardium. Moreover, since 
LC-MS/MS allows for the separation, identification and quantification of n-6 and n-3 PUFA-
derived lipid mediators, this methodology was used for lipid mediator identification and 



















4 RESULTS AND DISCUSSION 
Understanding the molecular and biological mechanisms behind how SPMs mediate their 
actions in cardiovascular diseases may further advance our understanding on how to stimulate 
the resolution of inflammation. This thesis unraveled some of the effects of n-3 PUFA and 
the actions of the EPA-derived SPM RvE1 signaling through ChemR23 in AVS (Article I), 
intimal hyperplasia (Article II) and atherosclerotic plaque calcification (Article III). 
n-3 PUFA, RvE1 and other SPMs are dysregulated in human cardiovascular diseases 
Starting in the context of AVS, we observed by gas chromatography that calcified regions of 
human aortic valves from AVS patients contained significantly lower amounts of n-3 PUFA 
compared with non-calcified regions. In addition, patients with fast AVS progression exhibited 
a trend towards lower incorporation of n-3 PUFA in non-calcified regions compared with 
patients with a slow progression.  
Since n-3 PUFA serve as precursor molecules for SPM biosynthesis, we also studied the 
presence of several SPMs in human aortic valves by LC-MS/MS. In our hands, and importantly 
for the first time, RvE1 and RvD3 were locally detected in aortic valve tissue. Moreover, RvE1 
was significantly decreased in calcified regions compared with non-calcified regions of the 
aortic valve. RvD3 was also lower in calcified regions. However, the difference did not reach 
statistical significance.  
Consistent with previous studies64, 238, the AA-derived LTB4 was found to be increased in 
calcified regions compared with non-calcified regions. LTB4 is a potent chemoattractant 
derived from the 5-lipoxygenase (5-LO) metabolism of AA, demonstrated to be detrimental 
not just in AVS, but also in intimal hyperplasia239 and atherosclerosis240, diseases that are also 
characterized by the presence of inflammatory cells.  
Overall, these results point to a non-resolved local inflammation in calcified regions of aortic 
valves, marked by a decreased RvE1/LTB4 ratio, which may be caused either by the impaired 
incorporation of n-3 PUFA in the aortic valve tissue or by a dysfunctional lipoxygenase 
metabolism into the downstream SPMs. Indeed, the ratio of resolvins and leukotrienes has 
previously been proposed as a marker of cardiovascular risk in several studies. For example, 
the RvD1/LTB4 ratio has been found to be lower in human vulnerable atherosclerotic plaques 
and the restoration of the ratio protects against plaque progression172. In another study, patients 
with a high salivary RvD1/LTB4 ratio have been shown to have a significantly lower intima 
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media thickness compared to patients with a low ratio, suggesting that RvD1/LTB4 can serve 
as a marker of non-resolved inflammation in the context of sub-clinical atherosclerosis241 
Transcriptomic analysis of aortic valves revealed that ChemR23 was the highest expressed 
receptor in the aortic valve compared with the RvD1 and RvD3 receptors ALX/FPR2, as well 
as GPR32, and with the RvD2 receptor GPR18. ChemR23 protein expression was further 
studied by immunohistochemistry (IHC) and by immunofluorescence (IF) confocal 
microscopy, showing co-localization with the VIC markers α-SMA as well as vimentin (Figure 
11). It is important to mention that ChemR23 in atherosclerotic plaques co-localizes with the 
VSMC marker α-SMA in a similar manner199. 
 
Figure 11. ChemR23 is expressed in human aortic valves. Representative immunofluorescence micrographs of 
human aortic valves. Vimentin (green), ChemR23 (red), and co-localization. Nuclei are stained blue.  
One important hallmark of AVS and atherosclerosis is calcification. Knowing that RvE1 is 
dysregulated in calcified regions of aortic valves together with the observation of ChemR23 
being highly expressed in VICs, we aimed to unravel the potential role of RvE1 in decreasing 
VIC calcification. Interestingly RvE1 treatment significantly decreased VIC calcification 
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induced by a high Pi concentration in vitro (Figure 12). This effect could be partially explained 
by extrapolating previous findings in VSMCs, where RvE1 also reduces calcification via 
downregulating BMP2 expression, hallmark of osteoblastic differentiation of vascular cells202. 
 
Figure 12. RvE1 decreases VIC Pi-induced calcification after 9 days of treatment. 
n-3 PUFA reduce AVS, atherosclerotic plaque calcification and intimal hyperplasia in 
mice 
Next, in vivo experiments were performed in order to decipher the mechanisms behind the n-3 
PUFA/ RvE1/ChemR23 axis in cardiovascular disease. We first inserted the Fat-1 transgene 
(Fat-1tg), encoding a n-3 PUFA desaturase which allows the conversion of dietary n-6 PUFA 
into n-3 PUFA, in the Apoe-/- mouse model of atherosclerosis and AVS. We also inserted the 
Fat-1tg in a normolipidemic background mouse (Apoe+/+) in order to elucidate the effects of n-
3 PUFA in a mouse model for intimal hyperplasia independent of hypercholesterolemia. 
We and other research groups have previously described that exogenous supplementation of n-
3 PUFA increases RvE1 formation199, as well as endogenous supplementation due to the 
presence of Fat-1tg 242, 243. However, the effects of RvE1 have not been addressed previously in 
the context of AVS nor atherosclerotic plaque calcification. 
TOF-SIMS analysis revealed that n-3 PUFA incorporated in the aortic valve and 
atherosclerotic lesions of Fat-1tgxApoe-/- mice. It is important to note that no evidence showing 
n-3 PUFA incorporation in the aortic valve of Fat-1tg mice has previously been reported in the 
literature. As expected, the increase in n-3 PUFA was accompanied by a decrease in n-6 PUFA, 
observations that were further explored and confirmed in myocardial tissue of the same mice 
by gas chromatography. Interestingly, EPA and AA in Fat-1tg mouse atherosclerotic plaques 
were the only PUFA that remained significantly statistically different compared with Apoe-/- 
mice after multiple test adjustment, suggesting a potential dominant role of EPA in the 
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atherosclerotic plaque. Indeed, these results are in line with the previously mentioned clinical 
trial showing that EPA supplementation in high doses significantly reduces cardiovascular 
risk131 and induces atherosclerotic plaque regression178. Moreover, TOF-SIMS fatty acid 
profiling of myocardial tissue mirrored the atherosclerotic plaque profile demonstrating that 
the fatty acid signature in the myocardium reflects the content in the atherosclerotic plaque. 
Further characterization of atherosclerotic plaques by TOF-SIMS revealed that local 
cholesterol in atherosclerotic plaques is mostly present in the form of free cholesterol and not 
as cholesterol esters, a form that was found in the blood remnants surrounding the 
atherosclerotic plaques. Moreover, no differences between total cholesterol amounts were 
observed between Apoe-/- mice carrying and not carrying the Fat-1tg. 
Knowing that Fat-1tg mice incorporated n-3 PUFA within the aortic valve, we next 
characterized the AVS development in Apoe-/- mice with and without the Fat-1tg by 
echocardiography from 52 until 72 weeks of age. Fat-1tgxApoe-/- mice exhibited reduced AVS 
progression, having reduced transaortic peak velocity and increased cusp separation. Moreover, 
aortic valve histological analysis showed that Fat-1tgxApoe-/- mice exhibited a reduced cross-
sectional aortic valve leaflet area as well as calcification (calcification depicted in Figure 13A) 
compared with non-transgenic Apoe-/- mice at 72 weeks. Despite not showing reduced 
atherosclerotic plaque lesion size, probably due to the advanced age of the mice, Fat-1tgxApoe-
/- mice also exhibited reduced atherosclerotic plaque calcification compared with Apoe-/- mice 
(Figure 13B). These results are in line with previous observations from other groups showing 
that exogenous EPA supplementation decreases arterial calcification in Klotho-/- mice207.  
Furthermore, by using a model of a permanent left carotid ligation in normolipidemic mice, we 
demonstrated that Fat-1tg also induced beneficial effects by reducing intimal hyperplasia 
formation after 4 weeks of ligation compared with WT (ChemR23+/+) mice (Figure 13C). This 
observation is of particular importance since the reduction of intimal hyperplasia induced by 
Fat-1tg was not dependent on the lipid lowering effects of n-3 PUFA. 
ChemR23 deletion increases AVS, atherosclerotic plaque calcification and intimal 
hyperplasia 
In order to study whether the beneficial effects induced by Fat-1tg in AVS, atherosclerotic 
plaque calcification and intimal hyperplasia were mediated by the n-3 PUFA downstream SPM 
RvE1 signaling through ChemR23, we generated the ChemR23-deficient mouse (ChemR23-/ -
) in a Apoe-/- and normolipidemic background. ChemR23-/- mice were also generated in the 
presence of the Fat-1tg. 
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Interestingly, Apoe-/-xChemR23-/- mice exhibited a more pronounced AVS development 
compared with Apoe-/- mice at 72 weeks, observed by the significant increase in transaortic 
peak velocity, reduced cusp separation as well as increased cross-sectional aortic valve leaflet 
area and calcification (calcification depicted in Figure 13A) in histological examinations. The 
detrimental effects of ChemR23 deletion in AVS were further explored in a normolipidemic 
model (Apoe+/+) of AVS induced by a direct aortic valve wire injury. Consistent with the 
previous results, after 16 weeks of valve injury ChemR23-/- mice exhibited a higher transaortic 
peak velocity as well as increased leaflet thickness compared with ChemR23+/+ mice.  
In similarity to the observations in valves, Apoe-/-xChemR23-/- mice significantly increased 
atherosclerotic plaque size and calcification compared with Apoe-/- mice (Figure 13B). This is 
not the first observation demonstrating the beneficial role of ChemR23 in the development of 
atherosclerosis. Indeed, our laboratory has previously demonstrated the protective role of 
ChemR23 as an antiatherogenic receptor in macrophage signaling by means of decreasing 
inflammation, reducing oxLDL uptake, and enhancing phagocytosis. These effects translate 
into the observed reduced mouse atherosclerotic plaque size, as well as a reduced macrophage 
content and necrotic core formation199. 
In the same line, in the context of intimal hyperplasia, ChemR23-/- mice developed larger 
lesions compared with WT (ChemR23+/+) mice 4 weeks after a carotid ligation (Figure 13C).  
RvE1 reduces AVS and atherosclerotic plaque calcification through ChemR23 
Aortic valve n-3 PUFA incorporation by the presence of Fat-1tg in Apoe-/-xChemR23-/- mice 
did not improve echocardiographic parameters compared with Apoe-/-xChemR23-/-  and did not 
reduce cross-sectional aortic valve leaflet area nor calcification (calcification depicted in Figure 
13A).  
Interestingly, all-groups adjusted correlations between quantitative echocardiographic and 
histological parameters (cross-sectional aortic valve leaflet area and leaflet calcification) were 
statistically correlated, as well as the adjusted correlation between the histological parameters 
cross-sectional aortic valve leaflet area and leaflet calcification. However, partial correlations 
(which measure the level of association between two variables whilst removing the effect of 
third variables) between quantitative variables (for example, cross-sectional aortic valve leaflet 
area and leaflet calcification) showed non-significant correlations when excluding genotype 
effect. The lack of significance of the partial correlations between the different quantitative 
measures, indicates that the beneficial effects observed by the presence of Fat-1tg as well as the 
detrimental effects induced by ChemR23 deletion may only be driven by the genotype effect,  
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which suggests that the distinct observations between the different genotypes were caused 
through independent mechanisms. 
In a similar manner, atherosclerotic plaque calcification in Fat-1tgxApoe-/-xChemR23-/- mice 
was not reduced compared with Apoe-/-xChemR23-/- mice (Figure 13B).  
 
Figure 13. Fat-1tg reduces aortic valve and atherosclerotic plaque calcification as well as intimal 
hyperplasia, whereas targeted deletion of ChemR23 increases aortic valve and atherosclerotic plaque 
calcification as well as intimal hyperplasia in mice. (A) Aortic valve leaflets and (B) atherosclerotic plaque 
calcification stained with Alizarin red of 72 weeks old Apoe-/-, Fat-1tgxApoe-/-, Apoe-/-xChemR23-/- and Fat-
1tgxApoe-/-xChemR23-/- mice. (C) Carotid intimal hyperplasia in 14 weeks old WT, Fat-1tg, ChemR23-/- and Fat-
1tgxChemR23-/- mice, 4 weeks after carotid artery ligation. 
Overall, our results show that the beneficial effects of Fat-1tg in AVS and atherosclerotic plaque 
calcification were only observed in the presence of ChemR23, suggesting that the effects in 
both conditions were mediated by RvE1 signaling through its receptor. As a matter of fact, the 
important role of RvE1in atherosclerosis development has been previously explored in a study 





n-3 PUFA reduce intimal hyperplasia but not exclusively through ChemR23 
In contrast with the observations in AVS and atherosclerotic plaque calcification, Fat-1tg also 
reduced intimal hyperplasia in ChemR23-/- mice, suggesting that n-3 PUFA do not reduce 
intimal hyperplasia development solely by signaling via RvE1 through ChemR23 (Figure 
13C). Indeed, the effects of different SPMs in the development of intimal hyperplasia may be 
receptor-specific in both inflammatory and structural cells. A recent study has shown that RvE1 
treatment in mice protects against intimal hyperplasia after femoral artery injury by signaling, 
not through ChemR23, but through BLT1 in leukocytes to reduce the infiltration of monocytes, 
neutrophils as well as T-cells to the site of injury. In contrast, RvE1 treatment reduces VSMCs 
migration signaling through ChemR23, and not through BLT1201.  
The fact that Fat-1tg also reduced intimal hyperplasia in the absence of ChemR23 potentially 
suggests that the beneficial effects may come from other n-3 PUFA-derived SPMs. Other SPMs 
have been described as having a beneficial role in the development of intimal hyperplasia. For 
example, administration of RvD1 and PD1 in rats and rabbits after artery balloon injury reduces 
macrophage, T-cell and neutrophil infiltration229, 245, 246. Moreover, other preclinical studies 
have shown that RvD2 and Mar1 induce M2 macrophage polarization after carotid ligation225. 
Furthermore, RvD1 and RvD2 reduce VSMC migration and proliferation as well as reduce 
collagen deposition246, 247 and NFκB activation in inflammatory cells, mitigating the 
inflammatory environment. This translates to reduced expression levels of IL-1β, IL-6248 and 
MCP1225. It is important to note that other studies have described a direct role of n-3 PUFA in 
decreasing intimal hyperplasia by directly binding to the free-fatty acid receptor-4249, which 
suggest another potential beneficial role of n-3 PUFA independent of SPM generation. 
In summary, our results revealed a protective role of n-3 PUFA supplementation and a 
detrimental role of ChemR23 deletion both in AVS, atherosclerotic plaque calcification and 
intimal hyperplasia. Interestingly, a specific dominancy of RvE1 signaling through ChemR23 
was only observed in the context of AVS and atherosclerotic plaque calcification, with a 
reduction of cross-sectional aortic valve leaflet area and calcification as well as atherosclerotic 
plaque calcification. 
Macrophage ChemR23 deletion promotes inflammation 
So far, the results presented in this thesis have demonstrated the detrimental effect of ChemR23 
deletion in inflammatory mouse models for AVS, atherosclerotic plaque calcification and 
intimal hyperplasia. However, a previous study from our laboratory has shown that the 
presence of ChemR23 is associated with increased vascular calcification in a non-inflammatory 
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model of medial calcification induced by high doses of vitamin D3202. This effect was 
explained to be mediated by a direct VSMC phenotypic switching into a synthetic and 
proliferative phenotype, coupled to the presence of ChemR23.  
This was further explored in this thesis, where it was observed that indeed, ChemR23+/+ mouse 
VSMCs exhibited a significantly higher proliferation than ChemR23-/- VSMCs in vitro. 
However, VSMCs treated with conditioned media from ChemR23-/- macrophages proliferated 
more than VSMCs treated with media from ChemR23+/+ macrophages. A later macrophage 
characterization demonstrated a more pro-inflammatory phenotype of ChemR23-/- compared 
with ChemR23+/+ macrophages, marked by the significantly increased levels of tumor necrosis 
factor (TNF) α, MMP9 and a trend for IL-6. For this reason, we concluded that the increased 
detrimental effects mediated by ChemR23 deletion in the in vivo models of AVS, 
atherosclerosis and intimal hyperplasia may be mediated by the pro-inflammatory macrophage 
effects.  
RvE1 signaling through ChemR23 promotes M2 macrophage polarization 
Distinct macrophage subpopulations are known to play different roles in atherosclerotic 
plaques 250 and stenotic aortic valves251. We studied the effects of n-3 PUFA and ChemR23 in 
macrophage polarization into the M1 and M2 subtypes by IHC, both in mouse aortic valves 
and atherosclerotic plaques. 
The characterization of macrophage populations in the mouse aortic valves revealed a higher 
expression of Arg1 as well as CD206 only in the presence of Fat-1tg, suggesting that high levels 
of n-3 PUFA increased macrophage polarization into M2 phenotype. Of note, Fat-1tg did not 
induce M2 polarization in the absence of ChemR23, once again showing that the beneficial 
effects of Fat-1tg were only present in mice with an intact ChemR23 expression. Lending 
support to this finding, mRNA levels of ChemR23 in human stenotic valves, both in non-
calcified and calcified tissue, were significantly correlated with the expression of several M2 
macrophage markers such as CD206, heme oxygenase (HMOX), CD163, CD209 and 
CD200R1.  
Furthermore, and in line with our observations in aortic valves, higher levels of Arg1 were 
found in atherosclerotic plaques of Fat-1tgxApoe-/- mice compared with Apoe-/- mice, as well 
as compared with Apoe-/- mice deficient in ChemR23, independently of the presence of Fat-
1tg. This further reinforces the idea that macrophage polarization was mediated by RvE1 
signaling through ChemR23, both in atherosclerotic plaques as well as in aortic valves. 
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Apart from being a marker of M2 macrophage phenotype, Arg1 has been described to play an 
important role in vascular calcification. As previously described, macrophages activated by 
high concentrations of Pi acquire anti-calcifying properties accompanied by a sharp increase in 
Arg1 and, interestingly, also of ChemR23153. These results are of particular importance for this 
thesis when taking into account recent evidence showing that Arg1 promotes macrophage 
efferocytosis of apoptotic cells by metabolizing the engulfed cell-derived arginine into 
putrescine. Putrescine activates macrophage Rac1 expression and facilitates further apoptotic 
cell internalization by promoting actin polymerization, thus increasing the resolution of the 
inflammatory process252, 253. This suggests that Arg1 expression, which in our experiments was 
induced by increased levels of n-3 PUFA solely in the presence of ChemR23, could potentially 
be considered a functional marker of macrophages with anti-calcifying and pro-resolving 
actions (Figure 14). 
Pi-activated macrophages mediate their anti-calcifying actions in part by reducing TNAP 
expression, thus promoting the accumulation of PPi in the extracellular space154. In line with 
this, we observed a trend towards a decreased mRNA expression of TNAP in the aorta of Apoe-
/- mice with enhanced n-3 PUFA levels by the insertion of Fat-1tg. Moreover, ChemR23 
deletion significantly increased TNAP expression in aortas of Fat-1tgxApoe-/- mice. This further 
supports the role of RvE1 in reducing atherosclerotic plaque and valvular calcification through 





Figure 14. The n-3 PUFA-derived RvE1 signaling through ChemR23 reduces cardiovascular calcification. 
Effects include increased M2 macrophage polarization, marked by the increased expression of Arg1, a protein 
associated with increased efferocytosis, as well as reduced TNAP expression levels, favoring the accumulation of 









5 CONCLUDING REMARKS 
Previous experimental studies have shown that n-3 PUFA exert a large number of beneficial 
effects in cardiovascular inflammation. As discussed throughout this thesis, one potential 
underlying mechanism relies in serving as a substrate for the biosynthesis of SPMs, which have 
been demonstrated to exert beneficial actions in several cardiovascular complications. The 
applicability of n-3 PUFA as a potential therapy in cardiovascular diseases has been supported 
in recent clinical trials showing a decreased risk of cardiovascular events, including 
cardiovascular death, and an enhanced atherosclerotic plaque regression by high-dose 
supplementation of EPA131, 178. 
Throughout this thesis, the role of n-3 PUFA, and specifically, the downstream EPA-derived 
SPM RvE1 signaling through its receptor ChemR23 has been studied in the context of AVS, 
intimal hyperplasia and atherosclerotic plaque calcification. 
In Article I, we provide evidence for the first time that n-3 PUFA accumulates both in human 
and murine aortic valves. Moreover, we describe that n-3 PUFA and RvE1 are decreased in 
calcified regions of human valves. In mice, increasing n-3 PUFA levels by the presence of Fat-
1tg halt AVS progression, reduce cross-sectional aortic valve leaflet area and calcification as 
well as promote macrophage polarization into the anti-inflammatory M2 phenotype, and 
importantly, only in the presence of ChemR23. Furthermore, ChemR23 deletion enhances 
AVS progression, and increases cross-sectional aortic valve leaflet area and calcification, 
effects that were not regressed by increasing the levels of n-3 PUFA, suggesting that the 
beneficial actions were mediated by the activation of the RvE1/ChemR23 signaling axis. 
In Article II, we established that deletion of ChemR23 increases intimal hyperplasia in mice. 
This effect may be caused by the fact that ChemR23-/- macrophages exhibit a more pro-
inflammatory phenotype, characterized by the increased expression of pro-inflammatory 
cytokines such as TNFα as well as MMP9.  
Interestingly, n-3 PUFA supplementation by the presence of Fat-1tg reduces intimal 
hyperplasia. However, n-3 PUFA beneficial effects were also observed in mice lacking the 
RvE1 receptor ChemR23, suggesting that other SPMs as well as other receptors apart from 
RvE1 and ChemR23, respectively, may have potential beneficial roles in this context. 
In Article III, we show that n-3 PUFA in mice are actively incorporated in the atherosclerotic 
plaque. We also decipher that a correct signaling through ChemR23 plays a critical role in the 
development of atherosclerotic plaque calcification. As a matter of fact, increased n-3 PUFA 
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reduces atherosclerotic plaque calcification, and the deletion of ChemR23 increases 
calcification, independently of the presence of Fat-1tg. The beneficial effects of n-3 PUFA may 
be mediated by a macrophage polarization into the anti-inflammatory/anti-calcification M2 
phenotype, marked by an increased expression of Arg1. Moreover, ChemR23 deletion 
significantly increased TNAP expression in Fat-1tg mice, suggesting that the n-3 PUFA effects 
may be mediated by an enhanced RvE1/ChemR23 signaling. 
In summary, the results presented in this thesis show the importance of the n-3 
PUFA/RvE1/ChemR23 axis in cardiovascular inflammation. This axis emerges as a potential 
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